Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 53, 2018 - Issue 6
Submit an article Journal homepage
517
Views
33
CrossRef citations to date
0
Altmetric
Original Article

Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience

Raguprakash RatnakumaranLeeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, UK; ;Leeds Gastroenterology Institute, St. James’ University Hospital, Leeds, UK
,
Natalie ToLeeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, UK; ;Leeds Gastroenterology Institute, St. James’ University Hospital, Leeds, UK
,
David J. GracieLeeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, UK; ;Leeds Gastroenterology Institute, St. James’ University Hospital, Leeds, UK
,
Christian P. SelingerLeeds Gastroenterology Institute, St. James’ University Hospital, Leeds, UK
,
Anthony O'ConnorLeeds Gastroenterology Institute, St. James’ University Hospital, Leeds, UK
,
Tanya ClarkLeeds Gastroenterology Institute, St. James’ University Hospital, Leeds, UK
,
Nicola CareyLeeds Gastroenterology Institute, St. James’ University Hospital, Leeds, UK
,
Katherine LeighLeeds Gastroenterology Institute, St. James’ University Hospital, Leeds, UK
,
Lynsey BournerLeeds Gastroenterology Institute, St. James’ University Hospital, Leeds, UK
,
Alexander C. FordLeeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, UK; ;Leeds Gastroenterology Institute, St. James’ University Hospital, Leeds, UKCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0001-6371-4359
ORCID Icon &
P. John HamlinLeeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, UK; ;Leeds Gastroenterology Institute, St. James’ University Hospital, Leeds, UK
 show all
Pages 700-707 | Received 26 Jan 2018, Accepted 02 Apr 2018, Published online: 24 Apr 2018

Citations (33)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Chiara Gasteiger, Alfons A. den Broeder, Sarah Stewart, Norina Gasteiger, Urte Scholz, Nicola Dalbeth & Keith J. Petrie. (2023) The mode of delivery and content of communication strategies used in mandatory and non-mandatory biosimilar transitions: a systematic review with meta-analysis. Health Psychology Review 17:1, pages 148-168.
Read now
Per M. Hellström, Eric Gemmen, Heather A. Ward, Hyewon Koo, Freddy Faccin, Zhenyi Xue & Petter Malmborg. (2022) Switching from originator infliximab to biosimilar versus continuing on originator in inflammatory bowel disease: results from the observational Project NORTH study. Scandinavian Journal of Gastroenterology 57:12, pages 1435-1442.
Read now
Rovshan M. Ismailov, Lieven Pouillon, Christian P. Selinger & Zaytuna D. Khasanova. (2021) Knowledge and awareness of biosimilars and shared decision-making among gastroenterology team members in Colorado, USA. Expert Opinion on Biological Therapy 21:1, pages 111-119.
Read now
Cristian Gheorghe, Pavel Svoboda & Bogdan Mateescu. (2019) Effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting in patients with Crohn’s disease or ulcerative colitis. Journal of Drug Assessment 8:1, pages 129-134.
Read now

Articles from other publishers (29)

Tomoe Kazama, Katsuyoshi Ando, Nobuhiro Ueno, Mikihiro Fujiya, Takahiro Ito, Atsuo Maemoto, Keisuke Ishigami, Masanori Nojima & Hiroshi Nakase. (2023) Long-term effectiveness and safety of infliximab-biosimilar: A multicenter Phoenix retrospective cohort study. PLOS ONE 18:9, pages e0288393.
Crossref
Ross M. Maltz, Madeline G. McClinchie, Brendan M. Boyle, Megan McNicol, Grant A. Morris, Erin C. Crawford, Jonathan MosesSandra C. Kim. (2023) Biosimilars for Pediatric Patients With Inflammatory Bowel Disease: Pediatric Gastroenterology Clinical Practice Survey. Journal of Pediatric Gastroenterology & Nutrition 76:5, pages 616-621.
Crossref
Anat Fisher, Jason D. Kim & Colin R. Dormuth. (2023) Monitoring a Mandatory Nonmedical Switching Policy from Originator to Biosimilar Infliximab in Patients with Inflammatory Bowel Diseases: A Population-Based Cohort Study. Gastroenterology Research and Practice 2023, pages 1-13.
Crossref
Marko Krstic, Jean-Christophe Devaud, Joachim Marti & Farshid Sadeghipour. (2022) Exploring the Reasons Behind the Substantial Discontinuation Rate Among Patients Taking CT-P13 in a Large Tertiary Hospital in Western Switzerland: A Retrospective Cohort Study Using Routinely Collected Medical Data. Drugs - Real World Outcomes 9:3, pages 425-436.
Crossref
Eleonora Allocati, Brian Godman, Marco Gobbi, Silvio Garattini & Rita Banzi. (2022) Switching Among Biosimilars: A Review of Clinical Evidence. Frontiers in Pharmacology 13.
Crossref
Yifei Liu, Martha Skup, Min Yang, Cynthia Z. Qi & Eric Q. Wu. (2022) Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018. Advances in Therapy 39:8, pages 3711-3734.
Crossref
Lina Yossef, Molly Wright, Jason Benedict, Grant A. Morris, Megan McNicol, Brendan Boyle, Jennifer L. DotsonHilary K. Michel & Ross M. Maltz. (2022) Patient and Caregivers’ Perspectives on Biosimilar Use in Pediatric Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology & Nutrition 75:1, pages 59-63.
Crossref
Bincy Abraham, Bertus Eksteen, Khan Nedd, Hrishikesh Kale, Dipen Patel, Jennifer Stephens, Ahmed Shelbaya, Richard Chambers & Arif Soonasra. (2022) Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study). Advances in Therapy 39:5, pages 2109-2127.
Crossref
Rosanne W. Meijboom, Helga Gardarsdottir, Toine C. G. Egberts & Thijs J. Giezen. (2021) Patients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review. BioDrugs 36:1, pages 27-39.
Crossref
Erin Hillhouse, Karine Mathurin, Joëlle Bibeau, Diana Parison, Yasmine Rahal, Jean Lachaine & Catherine Beauchemin. (2021) The Economic Impact of Originator-to-Biosimilar Non-medical Switching in the Real-World Setting: A Systematic Literature Review. Advances in Therapy 39:1, pages 455-487.
Crossref
Ross M Maltz, Megan McNicol, Laura Wingate, Sarah Buchanan, Angela Sandell, Sandra C Kim & David T Rubin. (2021) There Is No Substitute for Effective Education About Biosimilars. Crohn's & Colitis 360 3:4.
Crossref
Richard H. ParrishIIII. (2021) Biosimilar Interchangeability and Emerging Treatment Strategies for Inflammatory Bowel Diseases: A Commentary. Gastroenterology Insights 12:3, pages 293-301.
Crossref
Ana Martínez-Feito, Luz Yadira Bravo-Gallego, Borja Hernández-Breijo, Jesús Diez, Laura García-Ramirez, Marta Jaquotot, Chamaida Plasencia-Rodríguez, Pilar Nozal, Araceli Mezcua, María Dolores Martín- Arranz & Dora Pascual-Salcedo. (2020) Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar. Scientific Reports 10:1.
Crossref
Natália Sousa Freitas QUEIROZ, Rogerio SAAD-HOSSNE, Renata de Sá Brito FRÓES, Francisco Guilherme Cancela e PENNA, Stefania Burjack GABRIEL, Adalberta Lima MARTINS & Fabio Vieira TEIXEIRA. (2020) DISCONTINUATION RATES FOLLOWING A SWITCH FROM A REFERENCE TO A BIOSIMILAR BIOLOGIC IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS. Arquivos de Gastroenterologia 57:3, pages 232-243.
Crossref
Sang Joon Lee, KyungMin Baek, Sujin Lee, Yoon Jee Lee, Jeong Eun Park & Seul Gi Lee. (2020) Post-Marketing Pooled Safety Analysis for CT-P13 Treatment of Patients with Immune-Mediated Inflammatory Diseases in Observational Cohort Studies. BioDrugs 34:4, pages 513-528.
Crossref
Edmond-Jean Bernard, Richard N. Fedorak & Vipul Jairath. (2020) Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease. Digestive Diseases and Sciences 65:8, pages 2354-2372.
Crossref
Christian P Selinger. (2020) Biologicals are the main contributor to cost of care for IBD: a European perspective. The Lancet Gastroenterology & Hepatology 5:5, pages 421-422.
Crossref
Archana Kumari, Deo Nandan Prasad, Sahil Kumar & Rajesh K. Singh. (2020) Clinical Benefits of Switching from Original Infliximab to its Biosimilar (CT-P13) as a Potential TNF-α Inhibitor. Journal of Exploratory Research in Pharmacology 000:000, pages 1-9.
Crossref
Tomoo Nakagawa, Taku Kobayashi, Kiyohiro Nishikawa, Fumika Yamada, Satoshi Asai, Yukinori Sameshima, Yasuo Suzuki, Mamoru Watanabe & Toshifumi Hibi. (2019) Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice. Intestinal Research 17:4, pages 504-515.
Crossref
Mahmoud Ahmed Ebada, Abdelmagid M. Elmatboly, Ahmed Said Ali, Ahmed Mohamed Ibrahim, Notila Fayed, Ahmed Faisal Faisal & Souad Alkanj. (2019) An updated systematic review and meta-analysis about the safety and efficacy of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease. International Journal of Colorectal Disease 34:10, pages 1633-1652.
Crossref
Yifei Liu, Min Yang, Vishvas Garg, Eric Q. Wu, Jessie Wang & Martha Skup. (2019) Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review. Advances in Therapy 36:8, pages 1851-1877.
Crossref
Nikolas Plevris, Gareth R. Jones, Philip W. Jenkinson, Mathew Lyons, Cher S. Chuah, Lynne M. Merchant, Rebecca J. Pattenden, Eleanor F. Watson, Gwo-Tzer Ho, Colin L. Noble, Shahida Din, Alan G. Shand, Ian D. Arnott & Charlie W. Lees. (2018) Implementation of CT-P13 via a Managed Switch Programme in Crohn’s Disease: 12-Month Real-World Outcomes. Digestive Diseases and Sciences 64:6, pages 1660-1667.
Crossref
Konstantinos Papamichael, Steve Lin, Matthew Moore, Garyfallia Papaioannou, Lindsey Sattler & Adam S. Cheifetz. (2019) Infliximab in inflammatory bowel disease. Therapeutic Advances in Chronic Disease 10, pages 204062231983844.
Crossref
Ágnes Milassin, Anna Fábián & Tamás Molnár. (2019) Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective. Therapeutic Advances in Gastroenterology 12, pages 175628481984274.
Crossref
Rosa Giuliani, Josep Tabernero, Fatima Cardoso, Keith Hanson McGregor, Malvika Vyas & Elisabeth G.E. de Vries. (2019) Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology. ESMO Open 4:2, pages e000460.
Crossref
María Fernanda Guerra Veloz, Federico Argüelles-Arias, Luisa Castro Laria, Belén Maldonado Pérez, Antonio Benítez Roldan, Raúl Perea Amarillo, Vicente Merino Bohórquez, Miguel Angel Calleja, Ángel Caunedo Álvarez & Ángel Vilches Arenas. (2018) Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease. World Journal of Gastroenterology 24:46, pages 5288-5296.
Crossref
Christian P Selinger, Isabel Carbery & Jamal Al-Asiry. (2018) The role of biologics in the treatment of patients with inflammatory bowel disease. British Journal of Hospital Medicine 79:12, pages 686-693.
Crossref
Cristina Scavone, Maurizio Sessa, Emilio Clementi, Giovanni Corrao, Roberto Leone, Alessandro Mugelli, Francesco Rossi, Edoardo Spina & Annalisa Capuano. (2018) Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study. BioDrugs 32:6, pages 607-617.
Crossref
. (2018) Infliximab. Reactions Weekly 1714:1, pages 230-230.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.